William Annett is Chief Executive Officer of OncoCyte, a molecular diagnostics company focused on the discovery, development and commercialization of novel, non-invasive liquid biopsy diagnostics for the early detection of cancer.. His diagnostics industry experience includes his service as CEO at BioFX Laboratories, Inc., which created innovative products in the in vitro diagnostics field and was successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company, which worked with a consortium of universities to develop blood tests for the major diseases of pregnancy. In addition, Mr. Annett has held significant management positions at Genentech and Accenture and has worked on the clinical development and commercialization of a wide range of drugs and diagnostics.
At Genentech, Mr. Annett led the Commercial Strategy group and was responsible for large operational projects with a $150 million budget and over four hundred team members. He also directed the Project Finance function for R&D, which supported all development pipeline products and more than 200 clinical trials.
Most recently, Mr. Annett was a Managing Director at Accenture where he founded, built, and headed Accenture’s West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory. His clients included most of the major biotech and pharmaceutical companies in the western United States.
Mr. Annett holds an MBA from the Harvard Business School.